EMAIL THIS PAGE TO A FRIEND

PloS one

Nasal sensitization with ragweed pollen induces local-allergic-rhinitis-like symptoms in mice.


PMID 25119881

Abstract

Recently, the concept of local allergic rhinitis (LAR) was established, namely rhinitis symptoms with local IgE production and negative serum antigen-specific IgE. However, the natural course of LAR development and the disease pathogenesis is poorly understood. This study investigated the pathophysiology of mice with allergic rhinitis that initially sensitized with ragweed pollen through the nasal route. Mice were nasally administrated ragweed pollen over consecutive days without prior systemic immunization of the allergen. Serial nasal sensitization of ragweed pollen induced an allergen-specific increase in sneezing, eosinophilic infiltration, and the production of local IgE by day 7, but serum antigen-specific IgE was not detected. Th2 cells accumulated in nose and cervical lymph nodes as early as day 3. These symptoms are characteristic of human LAR. Continual nasal exposure of ragweed pollen for 3 weeks resulted in the onset of classical AR with systemic atopy and adversely affected lung inflammation when the allergen was instilled into the lung. Fcer1a(-/-) mice were defective in sneezing but developed normal eosinophilic infiltration. Contrary, Rag2(-/-) mice were defective in both sneezing and eosinophilic infiltration, suggesting that T cells play a central role in the pathogenesis of the disease. These observations demonstrate nasal allergen sensitization to non-atopic individuals can induce LAR. Because local Th2 cell accumulation is the first sign and Th2 cells have a central role in the disease, a T-cell-based approach may aid the diagnosis and treatment of LAR.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

PRS1105
Anti-CCR3 (ab1) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
PRS1109
Anti-CCR3 (ab2) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2900012
Anti-CCR3 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA042421
Anti-IL13 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1303597
ANTI-SIGLEC5 (N-TERM) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1304847
ANTI-SIGLEC5 (N-TERM) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
HPA009085
Anti-SIGLEC5 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
WH0003596M1
Monoclonal Anti-IL13 antibody produced in mouse, clone 7E4, purified immunoglobulin, buffered aqueous solution
SAB1403976
Monoclonal Anti-IL13 antibody produced in mouse, clone 3H7, purified immunoglobulin, buffered aqueous solution
I3407 Monoclonal Anti-Interleukin-13 antibody produced in mouse, clone 32116.11, purified immunoglobulin, lyophilized powder
I4532 Monoclonal Anti-Interleukin-13 antibody produced in rat, clone 38213.11, purified immunoglobulin, lyophilized powder